Repositori URV

Autor segons l'article: Guijarro C; Civeira F; López-Miranda J; Masana L; Pedro-Botet J; Pintó X; Valdivielso P; Mostaza JM

Departament: Medicina i Cirurgia

Autor/s de la URV: Masana Marín, Luis

Paraules clau: Inhibitors of proprotein convertase subtilisin kexin 9 Homozygous familial hypercholesterolemia Heterozygous familial hypercholesterolemia Dyslipidemia Costs benefit analysis Atherosclerotic cardiovascular disease Arteriosclerosis homozygous familial hypercholesterole-mia dyslipidemia costs benefit analysis atherosclerotic cardiovascular disease <p>heterozygous familial hypercholesterolemia</p>

Resum: Aims: During 2019 and 2020 a series of meetings over the country were carried out, with the aim of explaining the methodology and criteria for the ellaboration of the recommendations on the use of iPCSK9, published by the Spanish Society of Atherosclerosis (SEA in Spanish). At the end of the meetings, a survey was conducted among the participants, in order to describe the prescription requirements of these drugs in the Spanish regions. Methodology: Butterfly Project was developed by a scientific Committee of experts in lipids. After the ellaboration of the materials for the project, a train the trainers program was carried out, imparted by 17 experts who were the Project coordinators. Later, 16 regional workshops were performed, with the attendance of 169 medical doctors involved in the management of hipercolesterolemia. The attendants responded the survey, where they were asked different questions on the use of iPCSK9 on their clinical practice. Results: A high heterogeneity among centers regarding the requirements and difficulties for iPCSK9 prescription was revealed. Twenty one per cent of responders indicated to have low difficulties to prescribe iPCSK9 in their hospitals, whereas 78% found moderate or high difficulties. The difficulties came from burocracy- administrative aspects (18%), restrictions in the indication (41%) and both (38%). In general, the obstacles did not depend on the hospital level, neither the speciality, or the presence of lipid units, although the existance of lipid units was associated with a higher number of patients treated with iPCSK9. The factors which were associated with higher difficulty in the prescription were: the presence of an approval committee in the hospitals, the frequency in the revision of the treatment by hospital pharmacy, the temporal cadence of the prescription, the profile of patients seen and the criteria followed by the specialists for the prescription. Conclusion: The results show important diferences in the treatment with iPCSK9 in the context of clinical practice in Spain. The analysis of these results will permit to make proposals regarding future actions addressed to reach the equity in the access to iPCSK9 in Spain, with the main aim of maximizing their potential benefit according to the patients profile.

Àrees temàtiques: Pharmacology (medical) Peripheral vascular disease Medicina iii Medicina i Cardiology and cardiovascular medicine

Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/

Adreça de correu electrònic de l'autor: luis.masana@urv.cat

Identificador de l'autor: 0000-0002-0789-4954

Data d'alta del registre: 2024-08-24

Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion

URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/

Referència a l'article segons font original: Clinica E Investigacion En Arteriosclerosis. 34 (1): 10-18

Referència de l'ítem segons les normes APA: Guijarro C; Civeira F; López-Miranda J; Masana L; Pedro-Botet J; Pintó X; Valdivielso P; Mostaza JM (2022). Situación en 2020 de los requerimientos para la utilización de inhibidores de PCSK9 en España: resultados de una encuesta nacional. Clinica E Investigacion En Arteriosclerosis, 34(1), 10-18. DOI: 10.1016/j.arteri.2021.07.002

Entitat: Universitat Rovira i Virgili

Any de publicació de la revista: 2022

Tipus de publicació: Journal Publications